Trending

biotech IPO

Calliditas hits $90m jackpot as biotech IPO craze continues

Calliditas hits $90m jackpot as biotech IPO craze continues

Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease

X

Calliditas hits $90m jackpot as biotech IPO craze continues

https://pharmaphorum.com/news/calliditas-hits-90m-jackpot-as-biotech-ipo-craze-continues/

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Genmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody

X

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

https://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/

Calliditas pushing on with kidney disease drug after IPO success

Calliditas pushing on with kidney disease drug after IPO success

Calliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it

X

Calliditas pushing on with kidney disease drug after IPO success

https://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/

Circassia a cautionary tale for UK biotech, says Grainger

Circassia a cautionary tale for UK biotech, says Grainger

The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.

X

Circassia a cautionary tale for UK biotech, says Grainger

https://pharmaphorum.com/views-and-analysis/circassia-cautionary-tale-uk-biotech-says-grainger/

Are biotech IPOs back in fashion?

Are biotech IPOs back in fashion?

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months

X

Are biotech IPOs back in fashion?

https://pharmaphorum.com/news/biotech-ipos-coming-back-fashion/

Cancer biotech BeyondSpring hit by weak IPO

Cancer biotech BeyondSpring hit by weak IPO

Hoping for $100m, biotech raises under $3.5 million on stock market

X

Cancer biotech BeyondSpring hit by weak IPO

https://pharmaphorum.com/news/cancer-drug-firm-beyondspring-downsizes-ipo/

Jounce set to make first biotech IPO of 2017

Jounce set to make first biotech IPO of 2017

Massachusetts-based company will test the waters for biotech sector

X

Jounce set to make first biotech IPO of 2017

https://pharmaphorum.com/news/jounce-gets-early-lead-2017-biotech-ipos/

Circassia leads UK biotech funding success

Circassia leads UK biotech funding success

Three separate fund-raising rounds – headed by Circassia’s £275 million placing and open offer – give a further

X

Circassia leads UK biotech funding success

https://pharmaphorum.com/news/circassia-leads-uk-biotech-funding-success/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com